Skin Cancers are uncommon malignancies distinct from more common types like melanoma, basal cell carcinoma, or squamous cell carcinoma. These include Merkel cell carcinoma, dermatofibrosarcoma protuberans, and cutaneous T-cell lymphoma, each with unique genetic and clinical features. Our company, with extensive expertise, is dedicated to advancing research and developing innovative therapies to address skin cancers.
Introduction to Skin Cancers
Skin cancers, including Merkel cell carcinoma, dermatofibrosarcoma protuberans, and cutaneous T-cell lymphoma, account for less than 1% of all skin cancers. These malignancies are distinct from common types like melanoma and basal cell carcinoma, with each presenting unique genetic mutations and clinical behaviors. The incidence of skin cancers is estimated to be around 0.5 to 1 per 100,000 individuals annually.
Fig.1 Summary of Uveal Melanoma (UM) Cellular Metabolism. (Han, A., Z. T. Schug, and A. E. Aplin., 2021)
Therapeutics Development for Skin Cancers
In the development of therapies for skin cancers, the focus is on applying innovative treatments to address these rare but aggressive tumors, aiming to enhance treatment outcomes.
Immunotherapy
Immunotherapy has shown significant promise in treating various skin cancers in recent years. Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, have demonstrated notable success in treating Merkel cell carcinoma. By activating the patient's immune system to recognize and destroy cancer cells, immunotherapy offers a new avenue for treating refractory or advanced-stage skin cancers.
Gene and Cell Therapies
Gene therapy and cell-based therapies hold potential for treating skin cancers. Gene therapy aims to repair or replace mutated genes through gene-editing or viral vectors, offering the possibility of long-term therapeutic benefits. In addition, cell therapies, such as CAR-T cell therapy, utilize genetically modified immune cells to target and kill cancer cells, showing potential in addressing certain skin cancers.
Table.1 Ongoing clinical trials on physicochemical combination therapies for the management of skin cancer (3.Oglesby, A., A. P. Algazi, and A. I. Daud., 2019)
| NCT Number |
Study Title |
Phase |
Completion of Study |
Current state |
| NCT04977453 |
GI-101 as a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors |
Phase 1 |
September 2024 |
Recruiting |
| NCT05498805 |
PD-1 Inhibitors with or Without Radiation in Advanced Melanoma |
Phase 2 |
August 15, 2025 |
Not yet recruiting |
| NCT03969004 |
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma |
Phase 3 |
February 28, 2027 |
Recruiting |
| NCT04879654 |
Toripalimab Combined with Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery |
Phase 2 |
May 1, 2026 |
Recruiting |
| NCT03025724 |
Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ |
N/A |
January 2020 |
Unknown |
| NCT03110159 |
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients |
Phase 1 |
January 2022 |
Recruiting |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
We offer a wide range of services to support the development of therapies for skin cancers. Our skilled team uses advanced technology and deep industry expertise to accelerate your therapeutic initiatives, providing specialized therapeutic development and disease model development services.
Therapeutic Development
- Small Molecule Drug
- Cell Therapy
- Gene Therapy
- Therapeutic Antibody
- Therapeutic Peptide
- Therapeutic mRNA
- Therapeutic Protein
Disease Model Development
- 2D Cell Models
- 3D Models
- Genetically Engineering Model
- Induced Disease Model
- Humanized Animal Model
- Syngeneic Model
- Xenograft Model
Types of Skin Cancers
Skin cancers encompass a diverse group of uncommon malignancies, each with distinct genetic and clinical characteristics. Understanding the different types of skin cancers is essential for developing effective treatment strategies.
| A-C |
D-K |
M-U |
- Acral Lentiginous Melanoma (ALM)
- Basal Cell Carcinoma (BCC)
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Cutaneous T-cell Lymphoma
|
- Dermatofibrosarcoma Protuberans (DFSP)
- Extramammary Paget's Disease (EMPD)
- Kaposi's Sarcoma
|
- Merkel Cell Carcinoma (MCC)
- Microcystic Adnexal Carcinoma (MAC)
- Sebaceous Carcinoma
- Undifferentiated Pleomorphic Sarcoma
|
Our company is dedicated to offering complete, one-stop preclinical development services, covering all aspects from disease model creation to cutting-edge therapeutic research. Additionally, we provide comprehensive drug metabolism and pharmacokinetics and drug safety evaluation services to ensure rigorous assessment and support for successful drug development.
If you are interested in our services, please don't hesitate to contact us.
References
- Han, A., Z. T. Schug, and A. E. Aplin. "Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma." Trends Cancer 7.8 (2021): 671-81.
- Garcia, A., K. Nelson, and V. Patel. "Emerging Therapies for Rare Cutaneous Cancers: A Systematic Review." Cancer Treat Rev 100 (2021): 102266.
- Oglesby, A., A. P. Algazi, and A. I. Daud. "Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers." Am J Clin Dermatol 20.6 (2019): 781-96.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
